Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
12:00pm, Saturday, 30'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
07:09am, Wednesday, 27'th May 2026
Mirum Pharmaceuticals NASDAQ: MIRM executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and add
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
08:05am, Thursday, 21'st May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026.
Mirum Pharma: A Rare Disease Growth Story to Watch
12:35pm, Wednesday, 20'th May 2026
Mirum Pharmaceuticals NASDAQ: MIRM is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum rece
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 14'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
11:56pm, Tuesday, 12'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes.
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
04:01pm, Tuesday, 12'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering.
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
01:21pm, Tuesday, 12'th May 2026
Mirum Pharmaceuticals is evolving into a rare disease commercialization platform with multiple late-stage assets and robust commercial execution. MIRM raised 2026 net product sales guidance to $660–
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 12'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
01:06pm, Thursday, 07'th May 2026
MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
11:21pm, Wednesday, 06'th May 2026
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings
07:01pm, Wednesday, 06'th May 2026
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare wit
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates
06:25pm, Wednesday, 06'th May 2026
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.3 per share a year ago.
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Wednesday, 06'th May 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript
